Lack of Efficacy of Dextromethorphan in Managing Alcohol Withdrawal
Authors:
- Chun-Hsin ChenCCChun-Hsin Chen
- Chun-Hung PanCPChun-Hung Pan
- Shih-Ku LinSLShih-Ku Lin
- 1 February 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 34 (1) , 149-152
Abstract
Alcohol withdrawal syndrome is associated with increased central N-methyl-D-aspartate (NMDA) glutamate transmission. Medications that reduce glutamate release or block NMDA overactivation have shown efficacy for treating alcohol withdrawal syndrome. Dextromethorphan (DXM), a widely used antitussive drug, is a low-affinity, noncompetitive NMDA antagonist with potential neuroprotective properties. This study, using a randomized, double-blind, placebo-controlled study design, examined the benefit of DXM in the management of acute alcohol withdrawal. Alcohol-dependent patients admitted for detoxification treatment and experiencing moderate alcohol withdrawal, as measured by a score greater than 10 on the revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar), were randomly assigned to receive either DXM 360 mg/d or an identical placebo for 7 days in a double-blind manner. All subjects received a concurrent dose of lorazepam 2 mg along with the initial administration of DXM or placebo and were given additional lorazepam (1 mg) as a rescue medication according to the symptom-triggered detoxification protocol. Outcome measures consisted of the mean total dose of lorazepam received, the sequential scores on the CIWA-Ar, and craving assessed by the Obsessive-Compulsive Drinking Scale. Forty subjects completed the study, 18 in the DXM group and 22 in the placebo group. We found that compared with placebo, DXM use was not associated with lower lorazepam doses to control alcohol withdrawal symptoms. The progression in CIWA-Ar and Obsessive-Compulsive Drinking Scale scores was also comparable between the 2 groups. Our preliminary results do not support the efficacy of high-dose DXM in reducing the need of benzodiazepines to treat withdrawal symptoms in alcohol-dependent patients.Keywords
This publication has 29 references indexed in Scilit:
- Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utilityTherapeutics and Clinical Risk Management, 2012
- Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependenceAddictive Behaviors, 2009
- Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomesJournal of Psychopharmacology, 2007
- Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and DiazepamAlcohol, Clinical and Experimental Research, 2007
- Dextromethorphan psychosis, dependence and physical withdrawalAddiction Biology, 2005
- Divalproex Sodium in Alcohol Withdrawal: A Randomized Double‐Blind Placebo‐Controlled Clinical TrialAlcohol, Clinical and Experimental Research, 2001
- Clinical Experience With Excitatory Amino Acid Antagonist DrugsStroke, 1995
- NMDA Receptors: Role in Ethanol Withdrawal SeizuresAnnals of the New York Academy of Sciences, 1992
- Dextromethorphan An Overview of Safety IssuesDrug Safety, 1992
- Ethanol Inhibits NMDA-Activated Ion Current in Hippocampal NeuronsScience, 1989